The various wild mice and inbred strains differ from one another in their susceptibility to retroviruses and retrovirus-induced diseases. These differences are due to allelic differences in specific mouse chromosomal genes, and we have been engaged in an ongoing effort to identify and characterize the mouse genes involved in this resistance.There are 5 host range subgroups of murine leukemia viruses (MLVs). Each of these subgroups enters mouse cells following binding to specific cell surface receptors. We collaborated with the laboratory of David Kabat to clone and characterize the receptor for the polytropic subgroup of MLVs. This gene, Rmc1, encodes a 696 amino acid protein with multiple membrane spanning domains. The gene maps to distal mouse Chromosome 1. Allelic variants of this gene act as a receptor for the xenotropic subgroup of MLVs. Our previous studies demonstrated that the wild mouse species M. castaneus is uniquely resistant to polytropic viruses and that this resistance is due to the presence of an altered version of the cell surface receptor. More recent genetic crosses now indicate that two additional genes in the wild mouse genetic background collaborate with Rmc1 to produce this resistance. Immunological assays indicate that these additional genes are likely to represent endogenous viral envelope genes that can interfere with receptor function.We continued to investigate the viral resistance gene, Rmcf, which is responsible for partial resistance to the polytropic class of leukemia viruses. We have transferred this resistance to a wild mouse genetic background by serial backcrossing and used these partial congenics to identify a tightly linked chromosomally integrated copy of the viral envelope. This viral envelope is a candidate for resistance that may function by blocking cell surface viral receptors. We are working on the cloning of this gene (Jung).We are also characterizing a serum factor found in most mice which inactivates leukemia viruses. We have shown that this factor does not inactivate viruses of the ecotropic and amphotropic host range groups, but that it strongly inactivates polytropic viruses and, less strongly, xenotropic viruses. We have determined that the presence of this factor is under single gene control and we have initiated a genome scan to identify the responsible locus (Adamson). We have identified a possible genetic linkage and we are now screening potential candidate genes known to map to this region. - Polytropic leukemia virus, virus receptor, resistance genes, serum neutralizing factor, M. castaneus

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000298-18
Application #
6288821
Study Section
Special Emphasis Panel (LVD)
Project Start
Project End
Budget Start
Budget End
Support Year
18
Fiscal Year
1999
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Domi, Arban; Moss, Bernard (2002) Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells. Proc Natl Acad Sci U S A 99:12415-20
Stittelaar, K J; Kuiken, T; de Swart, R L et al. (2001) Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19:3700-9
McCart, J A; Ward, J M; Lee, J et al. (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61:8751-7
Hu, Y; Lee, J; McCart, J A et al. (2001) Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy. J Virol 75:10300-8
Zhu, Y d; Rota, P; Wyatt, L et al. (2000) Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody. Virology 276:202-13
Stittelaar, K J; Wyatt, L S; de Swart, R L et al. (2000) Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 74:4236-43
Men, R; Wyatt, L; Tokimatsu, I et al. (2000) Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18:3113-22
Wyatt, L S; Whitehead, S S; Venanzi, K A et al. (1999) Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18:392-7
Durbin, A P; Cho, C J; Elkins, W R et al. (1999) Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 J Infect Dis 179:1345-51
Nam, J H; Wyatt, L S; Chae, S L et al. (1999) Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine 17:261-8